RxDoctor Payments Data

Francis Mae Magdadaro

Nurse Practitioner · Anaheim, CANPI 1376200337

Payments from drug & device makers

$12,786in general payments, 2019–2025

Across 525 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $4K from 20 others

What the payments were for

  • Food & beverage$12,64899%
  • Education$1381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,786 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$27,251
Medicare patients
64
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl28$49,288
RexultiBrexpiprazole11$19,565
Lurasidone Hcl13$4,598
Quetiapine Fumarate ErQuetiapine Fumarate32$4,249
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,466
Quetiapine Fumarate54$976
Risperidone OdtRisperidone13$972
Aripiprazole34$924
Duloxetine Hcl47$907
Bupropion XlBupropion Hcl48$905
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$851
Divalproex Sodium19$637
Lamotrigine74$620
Mirtazapine50$604
Buspirone Hcl34$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,354$49,28828 claims
Otsuka America Pharmaceutical, Inc.Rexulti$932$19,56511 claims
Almatica Pharma LLCSertraline Hcl$175$39750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →